Kopp Family Office Reduces Stake in Viridian Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 hours ago
0mins
Should l Buy VRDN?
Source: Fool
- Stake Reduction Details: Kopp Family Office reduced its stake in Viridian Therapeutics by 117,878 shares in Q1 2026, with an estimated transaction value of $3.5 million, resulting in a decrease in the stake's representation from 3.4% to 0.7% of AUM, indicating a cautious outlook on the company's future performance.
- Financial Performance Analysis: Viridian reported a net loss of $343 million for 2025, up from $270 million the previous year, despite maintaining a strong cash position of approximately $875 million, highlighting increased spending pressures related to clinical trials and commercial preparations.
- Market Competition Dynamics: In March 2026, Viridian's elegrobart candidate met primary endpoints in Phase 3 trials but faced poor market reaction, with shares dropping over 30% on the report day, while Amgen's competing product Tepezza demonstrated superior efficacy, intensifying market competition.
- Investor Strategy Adjustments: Kopp's stake reduction does not imply a total loss of confidence in Viridian but reflects routine management of high-risk investments, particularly in light of strong competitors like Amgen, leading investors to prefer diversified exposure through healthcare ETFs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRDN
Wall Street analysts forecast VRDN stock price to rise
17 Analyst Rating
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.680
Low
14.20
Averages
41.71
High
61.00
Current: 14.680
Low
14.20
Averages
41.71
High
61.00
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kopp Family Office Reduces Stake in Viridian Therapeutics
- Stake Reduction Details: Kopp Family Office reduced its stake in Viridian Therapeutics by 117,878 shares in Q1 2026, with an estimated transaction value of $3.5 million, resulting in a decrease in the stake's representation from 3.4% to 0.7% of AUM, indicating a cautious outlook on the company's future performance.
- Financial Performance Analysis: Viridian reported a net loss of $343 million for 2025, up from $270 million the previous year, despite maintaining a strong cash position of approximately $875 million, highlighting increased spending pressures related to clinical trials and commercial preparations.
- Market Competition Dynamics: In March 2026, Viridian's elegrobart candidate met primary endpoints in Phase 3 trials but faced poor market reaction, with shares dropping over 30% on the report day, while Amgen's competing product Tepezza demonstrated superior efficacy, intensifying market competition.
- Investor Strategy Adjustments: Kopp's stake reduction does not imply a total loss of confidence in Viridian but reflects routine management of high-risk investments, particularly in light of strong competitors like Amgen, leading investors to prefer diversified exposure through healthcare ETFs.
See More
Viridian Reveals Partnership Agreement with Outside the Box Capital for Market Services
Announcement of Agreement: Viridian has announced a new agreement for market services with Outside the Box Capital.
Focus on Market Services: The partnership aims to enhance market services, potentially expanding both companies' reach and capabilities in the financial sector.
See More
Surge in Options Trading Volume for OraSure and Viridian
- OraSure Options Volume: OraSure Technologies Inc. experienced options trading volume of 3,510 contracts, representing approximately 351,000 shares, which is about 62.6% of its average daily trading volume of 560,775 shares over the past month, indicating heightened market interest in its future performance.
- High Demand for Call Options: Notably, the $2.50 strike call option expiring on April 17, 2026, saw trading of 3,500 contracts today, representing around 350,000 shares, suggesting investor optimism regarding OraSure's prospects.
- Viridian Options Volume: Viridian Therapeutics Inc. recorded options trading volume of 14,194 contracts, equating to approximately 1.4 million shares, or about 61% of its average daily trading volume of 2.3 million shares over the past month, reflecting strong investor interest in the company.
- Active Trading of Put Options: Particularly, the $14 strike put option expiring on May 15, 2026, has seen trading of 5,002 contracts today, representing approximately 500,200 shares, indicating market concerns regarding potential risks facing Viridian in the future.
See More
Amgen's Phase 3 Trial Success Leads to Viridian Stock Plunge
- Amgen Trial Results: Amgen's Phase 3 trial achieved its primary goal, with 77% of patients showing significant improvement in eye bulging, indicating the effectiveness of its drug Tepezza for thyroid eye disease, which could positively impact market dynamics.
- Viridian Drug Performance: Viridian's Elegrobar reduced eye bulging by approximately 54% and 63% over four and eight weeks, respectively, although its efficacy is lower than Amgen's; however, its simpler subcutaneous injection method may provide a competitive edge in the market.
- Stock Price Volatility: Viridian's shares plummeted 23% on Monday, hitting the lowest point since June 3, 2025, reflecting market disappointment over its Phase 3 trial results, particularly due to limited inflammation improvement and reports of tinnitus.
- Market Sentiment Shift: Despite the stock's decline, retail sentiment on Stocktwits shifted from 'extremely bullish' to 'bullish', indicating some market participants expect a rebound, with predictions of the stock rising to $25 by the end of the week.
See More
Viridian Therapeutics Shares Plummet: The Connection to an Amgen Study Explained.
- Viridian Therapeutics Stock Reaction: Viridian Therapeutics' stock experienced a decline on Monday.
- Amgen's Phase 3 Trial Results: The drop followed Amgen's announcement of positive results from a Phase 3 trial for a new treatment targeting thyroid eye disease.
See More
Stock Movers: Seagate, Micron, Tesla, Kratos, Strategy, Soleno, Viridian, and Others
- Market Reaction: Stocks experienced an increase on Monday as investors remained optimistic about a potential peace agreement between the U.S. and Iran.
- Deadline Pressure: The optimism is linked to a looming Tuesday evening deadline concerning threatened strikes on power plants by the president.
See More
Kopp Family Office Reduces Stake in Viridian Therapeutics
- Stake Reduction Details: Kopp Family Office reduced its stake in Viridian Therapeutics by 117,878 shares in Q1 2026, with an estimated transaction value of $3.5 million, resulting in a decrease in the stake's representation from 3.4% to 0.7% of AUM, indicating a cautious outlook on the company's future performance.
- Financial Performance Analysis: Viridian reported a net loss of $343 million for 2025, up from $270 million the previous year, despite maintaining a strong cash position of approximately $875 million, highlighting increased spending pressures related to clinical trials and commercial preparations.
- Market Competition Dynamics: In March 2026, Viridian's elegrobart candidate met primary endpoints in Phase 3 trials but faced poor market reaction, with shares dropping over 30% on the report day, while Amgen's competing product Tepezza demonstrated superior efficacy, intensifying market competition.
- Investor Strategy Adjustments: Kopp's stake reduction does not imply a total loss of confidence in Viridian but reflects routine management of high-risk investments, particularly in light of strong competitors like Amgen, leading investors to prefer diversified exposure through healthcare ETFs.
See More
Viridian Reveals Partnership Agreement with Outside the Box Capital for Market Services
Announcement of Agreement: Viridian has announced a new agreement for market services with Outside the Box Capital.
Focus on Market Services: The partnership aims to enhance market services, potentially expanding both companies' reach and capabilities in the financial sector.
See More
Surge in Options Trading Volume for OraSure and Viridian
- OraSure Options Volume: OraSure Technologies Inc. experienced options trading volume of 3,510 contracts, representing approximately 351,000 shares, which is about 62.6% of its average daily trading volume of 560,775 shares over the past month, indicating heightened market interest in its future performance.
- High Demand for Call Options: Notably, the $2.50 strike call option expiring on April 17, 2026, saw trading of 3,500 contracts today, representing around 350,000 shares, suggesting investor optimism regarding OraSure's prospects.
- Viridian Options Volume: Viridian Therapeutics Inc. recorded options trading volume of 14,194 contracts, equating to approximately 1.4 million shares, or about 61% of its average daily trading volume of 2.3 million shares over the past month, reflecting strong investor interest in the company.
- Active Trading of Put Options: Particularly, the $14 strike put option expiring on May 15, 2026, has seen trading of 5,002 contracts today, representing approximately 500,200 shares, indicating market concerns regarding potential risks facing Viridian in the future.
See More
Amgen's Phase 3 Trial Success Leads to Viridian Stock Plunge
- Amgen Trial Results: Amgen's Phase 3 trial achieved its primary goal, with 77% of patients showing significant improvement in eye bulging, indicating the effectiveness of its drug Tepezza for thyroid eye disease, which could positively impact market dynamics.
- Viridian Drug Performance: Viridian's Elegrobar reduced eye bulging by approximately 54% and 63% over four and eight weeks, respectively, although its efficacy is lower than Amgen's; however, its simpler subcutaneous injection method may provide a competitive edge in the market.
- Stock Price Volatility: Viridian's shares plummeted 23% on Monday, hitting the lowest point since June 3, 2025, reflecting market disappointment over its Phase 3 trial results, particularly due to limited inflammation improvement and reports of tinnitus.
- Market Sentiment Shift: Despite the stock's decline, retail sentiment on Stocktwits shifted from 'extremely bullish' to 'bullish', indicating some market participants expect a rebound, with predictions of the stock rising to $25 by the end of the week.
See More
Viridian Therapeutics Shares Plummet: The Connection to an Amgen Study Explained.
- Viridian Therapeutics Stock Reaction: Viridian Therapeutics' stock experienced a decline on Monday.
- Amgen's Phase 3 Trial Results: The drop followed Amgen's announcement of positive results from a Phase 3 trial for a new treatment targeting thyroid eye disease.
See More
Stock Movers: Seagate, Micron, Tesla, Kratos, Strategy, Soleno, Viridian, and Others
- Market Reaction: Stocks experienced an increase on Monday as investors remained optimistic about a potential peace agreement between the U.S. and Iran.
- Deadline Pressure: The optimism is linked to a looming Tuesday evening deadline concerning threatened strikes on power plants by the president.
See More
